# VitriVax raises $87M for Lyme vaccine

> VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine.
- Title: VitriVax raises $87M for Lyme vaccine · Dealroom | Shortify
- Summary: VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine.
- Keywords: vitrivax, lyme disease vaccine, series c funding, pfizer, valneva, moderna, Dealroom
- URL: https://shortify.news/Dealroom/vitrivax-raises-87m-for-lyme-vaccine
- Source: Dealroom — https://dealroom.co/news/173944-vitrivax-raises-87m-series-c-to-chase-first-lyme-disease-vaccine
- Published: 2026-11-18T12:28:09+00:00
- Read time: 1 min
- Topics: vitrivax, lyme disease vaccine, series c funding, pfizer, valneva, moderna, startups, business
## Funding round
VitriVax raised $87 million Series C to develop Lyme disease vaccine.
## Market gap
No approved human Lyme vaccine exists, creating unmet need for new solution.
## Competitor status
Pfizer and Valneva's candidate faces regulatory uncertainty while VitriVax advances.
## Key takeaway

VitriVax raised $87 million Series C to pursue Lyme disease vaccine after no approved human vaccine exists.

---

Summary: Shortify — https://shortify.news/Dealroom/vitrivax-raises-87m-for-lyme-vaccine
Reporting: Dealroom — https://dealroom.co/news/173944-vitrivax-raises-87m-series-c-to-chase-first-lyme-disease-vaccine

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.